InvestorsHub Logo
Followers 1322
Posts 247420
Boards Moderated 55
Alias Born 12/07/2009

Re: ProfitScout post# 251

Thursday, 07/16/2020 8:19:32 AM

Thursday, July 16, 2020 8:19:32 AM

Post# of 3614
CURE’s CEO Rob Davidson, stated,

“CURE’s delivery platform, which includes the encapsulation technology gained via the Chemistry Holdings acquisition, might have commercial applications for CBD, especially when given in high doses. Moreover, when we consider that CURE’s buccal, or transmucosal, application technology may avoid first pass drug metabolism, we might see further improvements beyond those observed in this study. The potential to meet a large consumer base and unmet medical need is compelling.”

$CURR


ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.